| DI |
2026-07-20 17:30 |
2026-07-16 |
CBIO |
CRESCENT BIOPHARMA, INC. |
Fairmount Funds Management LLC |
Dir, 10% |
P - Purchase |
$14.50 |
+853.5K |
3.60M |
+31% |
+$12.38M |
| DI |
2026-07-01 21:30 |
2026-07-01 |
ORKA |
Oruka Therapeutics, Inc. |
Fairmount Funds Management LLC |
Dir, 10% |
C - Cnv Deriv |
— |
+3.55M |
4.69M |
+314% |
— |
| DI |
2026-07-01 21:30 |
2026-07-01 |
ORKA |
Oruka Therapeutics, Inc. |
Fairmount Funds Management LLC |
Dir, 10% |
S - Sale |
$84.43 |
-3.55M |
1.13M |
-76% |
-$300.01M |
| DI |
2026-06-23 21:56 |
2026-06-23 |
SYRE |
Spyre Therapeutics, Inc. |
Fairmount Funds Management LLC |
Dir |
C - Cnv Deriv |
— |
+666.7K |
4.68M |
+17% |
— |
| DI |
2026-06-23 21:56 |
2026-06-23 |
SYRE |
Spyre Therapeutics, Inc. |
Fairmount Funds Management LLC |
Dir |
S - Sale |
$85.31 |
-4.68M |
0 |
-100% |
-$399.66M |
| I |
2026-05-13 16:31 |
2026-05-11 |
VRDN |
Viridian Therapeutics, Inc.\DE |
Fairmount Funds Management LLC |
Dir, 10% |
P - Purchase |
$17.00 |
+1.18M |
5.09M |
+30% |
+$20.00M |
| I |
2026-04-01 16:30 |
2026-03-31 |
ZBIO |
Zenas BioPharma, Inc. |
Fairmount Funds Management LLC |
Dir |
P - Purchase |
$20.00 |
+150.0K |
2.36M |
+7% |
+$3.00M |
| DI |
2026-03-31 |
2026-03-31 |
COGT |
Cogent Biosciences, Inc. |
Fairmount Funds Management LLC |
Dir |
C - Cnv Deriv |
— |
+7.00M |
12.50M |
+127% |
— |
| DI |
2026-03-31 |
2026-03-31 |
COGT |
Cogent Biosciences, Inc. |
Fairmount Funds Management LLC |
Dir |
S - Sale |
$34.66 |
-7.00M |
5.50M |
-56% |
-$242.62M |
| I |
2026-01-22 |
2026-01-22 |
COGT |
Cogent Biosciences, Inc. |
Fairmount Funds Management LLC |
Dir |
S - Sale |
$36.40 |
-3.50M |
5.50M |
-39% |
-$127.40M |
| I |
2025-07-14 |
2025-07-10 |
COGT |
Cogent Biosciences, Inc. |
Fairmount Funds Management LLC |
Dir |
P - Purchase |
$9.00 |
+2.78M |
9.00M |
+45% |
+$25.00M |
| DMI |
2025-06-11 |
2025-06-09+ |
VRDN |
Viridian Therapeutics, Inc.\DE |
Fairmount Funds Management LLC |
Dir, 10% |
M - OptEx |
$11.80 |
+14.1K |
3.46M |
+0.4% |
+$166.4K |
| DMAI |
2024-09-17 |
2024-09-16 |
ZBIO |
Zenas BioPharma, Inc. |
Fairmount Funds Management LLC |
Dir |
C - Cnv Deriv |
— |
+1.30M |
329.0K |
New |
— |
| DAI |
2024-09-17 |
2024-09-16 |
ZBIO |
Zenas BioPharma, Inc. |
Fairmount Funds Management LLC |
Dir |
P - Purchase |
$17.00 |
+300.0K |
1.89M |
+19% |
+$5.10M |
| DI |
2024-06-12 |
2024-06-10 |
COGT |
Cogent Biosciences, Inc. |
Fairmount Funds Management LLC |
Dir |
M - OptEx |
— |
+1.50M |
6.23M |
+32% |
— |
| DMI |
2024-04-01 |
2024-03-28 |
COGT |
Cogent Biosciences, Inc. |
Fairmount Funds Management LLC |
Dir |
J - Other |
— |
0 |
0 |
New |
— |
| DI |
2024-02-16 |
2024-02-16 |
COGT |
Cogent Biosciences, Inc. |
Fairmount Funds Management LLC |
10% |
A - Grant |
$7.50 |
+1.17M |
4.44M |
+36% |
+$8.75M |
| DI |
2024-01-24 |
2024-01-22 |
DNTH |
Dianthus Therapeutics, Inc. /DE/ |
Fairmount Funds Management LLC |
Dir, 10% |
A - Grant |
$12.00 |
+834.3K |
2.76M |
+43% |
+$10.01M |
| I |
2023-06-13 |
2023-06-09 |
COGT |
Cogent Biosciences, Inc. |
Fairmount Funds Management LLC |
10%, See Remarks |
P - Purchase |
$12.00 |
+800.0K |
3.27M |
+32% |
+$9.60M |
| I |
2022-06-21 |
2022-06-16 |
COGT |
Cogent Biosciences, Inc. |
Fairmount Funds Management LLC |
10%, See Remarks |
P - Purchase |
$8.25 |
+1.20M |
2.47M |
+94% |
+$9.90M |